MEA Age-Related Macular Degeneration (AMD) Disease Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 26
1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.3 OVERVIEW OF MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET 26
1.4 LIMITATIONS 28
1.5 MARKETS COVERED 28
2 MARKET SEGMENTATION 31
2.1 MARKETS COVERED 31
2.2 GEOGRAPHICAL SCOPE 32
2.3 YEARS CONSIDERED FOR THE STUDY 33
2.4 CURRENCY AND PRICING 33
2.5 DBMR TRIPOD DATA VALIDATION MODEL 34
2.6 MULTIVARIATE MODELLING 37
2.7 TYPE LIFELINE CURVE 37
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 38
2.9 DBMR MARKET POSITION GRID 39
2.10 MARKET END USER COVERAGE GRID 40
2.11 VENDOR SHARE ANALYSIS 41
2.12 SECONDARY SOURCES 42
2.13 ASSUMPTIONS 42
3 EXECUTIVE SUMMARY 43
4 PREMIUM INSIGHTS 46
4.1 PESTEL 47
4.2 PORTER'S FIVE FORCES MODEL 48
5 REGULATORY FRAMEWORK 49
6 MARKET OVERVIEW 52
6.1 DRIVERS 54
6.1.1 RISING PREVALENCE OF AGE-RELATED MACULAR DEGENERATION 54
6.1.2 INCREASING GERIATRIC POPULATION 54
6.1.3 INCREASE IN PIPELINE PRODUCTS 55
6.1.4 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYERS 56
6.2 RESTRAINTS 56
6.2.1 HIGH COST OF TREATMENT AND PROCEDURES 56
6.2.2 LACK OF ENOUGH QUALIFIED PROFESSIONALS 57
6.3 OPPORTUNITIES 58
6.3.1 INCREASING RESEARCH AND DEVELOPMENT 58
6.3.2 INCREASE IN AWARENESS AND TREATMENT-SEEKING RATE OF AMD 58
6.3.3 EMERGING REIMBURSEMENT POLICIES FOR THE TREATMENT 59
6.3.4 INCREASING PRODUCT APPROVAL FOR AGE-RELATED MACULAR DEGENERATION (AMD) 59
6.4 CHALLENGES 60
6.4.1 LIMITED ACCESS TO TREATMENT 60
6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR PRODUCTS 60
7 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE 61
7.1 OVERVIEW 62
7.2 DRY AMD 65
7.3 WET AMD 65
7.3.1 MEDICATIONS 66
7.3.2 ANTI-VEGF THERAPY 67
7.3.3 GENE THERAPY 67
7.3.4 SURGERY 67
8 MIDDLE EAST & AFRICA AGE- RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER 68
8.1 OVERVIEW 69
8.2 HOSPITALS 72
8.3 SPECIALTY CLINICS 72
8.4 AMBULATORY SURGICAL CENTERS 73
8.5 HOME HEALTHCARE 74
8.6 OTHERS 75
9 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL 76
9.1 OVERVIEW 77
9.2 RETAIL SALES 81
9.2.1 HOSPITAL PHARMACIES 82
9.2.2 RETAIL PHARMACIES 82
9.2.3 OTHERS 82
9.3 DIRECT TENDER 82

10 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION 83
10.1 MIDDLE EAST & AFRICA 84
10.1.1 SOUTH AFRICA 91
10.1.2 SAUDI ARABIA 93
10.1.3 UAE 95
10.1.4 ISRAEL 97
10.1.5 EGYPT 99
10.1.6 KUWAIT 101
10.1.7 REST OF MIDDLE EAST & AFRICA 103
11 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: COMPANY LANDSCAPE 104
11.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 104
12 SWOT ANALYSIS 105
13 COMPANY PROFILE 106
13.1 NOVARTIS AG 106
13.1.1 COMPANY SNAPSHOT 106
13.1.2 REVENUE ANALYSIS 106
13.1.3 COMPANY SHARE ANALYSIS 107
13.1.4 PRODUCT PORTFOLIO 107
13.1.5 RECENT DEVELOPMENT 107
13.1.5.1 AGREEMENT 107
13.2 GENENTECH, INC. 108
13.2.1 COMPANY SNAPSHOT 108
13.2.2 COMPANY SHARE ANALYSIS 108
13.2.3 PRODUCT PORTFOLIO 109
13.2.4 RECENT DEVELOPMENT 109
13.3 BAYER AG 110
13.3.1 COMPANY SNAPSHOT 110
13.3.2 REVENUE ANALYSIS 110
13.3.3 COMPANY SHARE ANALYSIS 111
13.3.4 PRODUCT PORTFOLIO 111
13.3.5 RECENT DEVELOPMENT 111
13.4 ADVERUM BIOTECHNOLOGIES, INC. 112
13.4.1 COMPANY SNAPSHOT 112
13.4.2 REVENUE ANALYSIS 112
13.4.3 PRODUCT PORTFOLIO 112
13.4.4 RECENT DEVELOPMENT 113
13.5 ASTELLAS PHARMA INC. 114
13.5.1 COMPANY SNAPSHOT 114
13.5.2 REVENUE ANALYSIS 114
13.5.3 PRODUCT PORTFOLIO 115
13.5.4 RECENT DEVELOPMENT 115
13.6 GRAYBUG VISION INC. 116
13.6.1 COMPANY SNAPSHOT 116
13.6.2 REVENUE ANALYSIS 116
13.6.3 PRODUCT PORTFOLIO 116
13.6.4 RECENT DEVELOPMENT 117
13.7 GENSIGHT BIOLOGICS 118
13.7.1 COMPANY SNAPSHOT 118
13.7.2 REVENUE ANALYSIS 118
13.7.3 PRODUCT PORTFOLIO 119
13.7.4 RECENT DEVELOPMENTS 119
13.7.4.1 EVENT 119
13.7.4.2 AWARD 119
13.8 IONIS PHARMACEUTICALS 120
13.8.1 COMPANY SNAPSHOT 120
13.8.2 REVENUE ANALYSIS 120
13.8.3 PRODUCT PORTFOLIO 121
13.8.4 RECENT DEVELOPMENT 121
13.8.4.1 EVENT 121
13.9 IVERIC BIO 122
13.9.1 COMPANY SNAPSHOT 122
13.9.2 PRODUCT PORTFOLIO 122
13.9.3 RECENT DEVELOPMENT 122
13.10 JOHNSON &JOHNSON SERVICES, INC. 123
13.10.1 COMPANY SNAPSHOT 123
13.10.2 REVENUE ANALYSIS 123
13.10.3 PRODUCT PORTFOLIO 124
13.10.4 RECENT DEVELOPMENT 124
13.10.4.1 COLLABORATION 124
13.11 KODIAK SCIENCES INC. 125
13.11.1 COMPANY SNAPSHOT 125
13.11.2 PRODUCT PORTFOLIO 125
13.11.3 RECENT DEVELOPMENT 125

13.12 MEIRAGTX LIMITED 126
13.12.1 COMPANY SNAPSHOT 126
13.12.2 PRODUCT PORTFOLIO 126
13.12.3 RECENT DEVELOPMENTS 126
13.12.3.1 EVENTS 126
13.12.3.2 AWARD 127
13.12.3.3 COLLABORATION 127
13.13 OCUGEN INC. 128
13.13.1 COMPANY SNAPSHOT 128
13.13.2 PRODUCT PORTFOLIO 128
13.13.3 RECENT DEVELOPMENTS 128
13.13.3.1 INVESTMENT 128
13.13.3.2 CLINICAL TRIAL 129
13.14 PIXIUM VISION 130
13.14.1 COMPANY SNAPSHOT 130
13.14.2 REVENUE ANALYSIS 130
13.14.3 PRODUCT PORTFOLIO 130
13.14.4 RECENT DEVELOPMENT 131
13.14.4.1 AWARD 131
13.15 REGENXBIO INC. 132
13.15.1 COMPANY SNAPSHOT 132
13.15.2 PRODUCT PORTFOLIO 132
13.15.3 RECENT DEVELOPMENTS 132
13.15.3.1 EVENT 132
13.15.3.2 COLLABORATION 133
13.15.3.3 CERTIFICATION 133
14 QUESTIONNAIRE 134
15 RELATED REPORTS 137